Multiple in vivo and in vitro research studies suggest that statins might prevent or treat NASH via HSCs, LSECs, PON1, GTPase, PPARs, AMPK, and ferroptosis. Here, PON1 is linked to metabolic dysfunction-associated steatohepatitis.